Atossa Genetics is making moves!!
Atossa Genetics’ Preliminary Phase 2 Study Achieves Primary Endpoint: Topical Endoxifen Rapidly Reduces Breast Density
This is what we are looking for, go long with this CV company. Find a good entry point and squat!! If FDA approved this will go back where it cam from $$$
This is what we are looking for, go long with this CV company. Find a good entry point and squat!! If FDA approved this will go back where it cam from $$$
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.